Behera Dibyajyoti Uttameswar, Ratnajothy Keerthanan, Dey Suchanda, Gaur Mahendra, Sahoo Rajesh Kumar, Sahoo Saubhagini, Rautaraya Bibhudutta, Rout Manish Kumar, Subudhi Enketeswara
Centre for Biotechnology, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Kalinga Nagar, Ghatikia, Bhubaneswar, Odisha 751003 India.
Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha 751003 India.
3 Biotech. 2023 May;13(5):127. doi: 10.1007/s13205-023-03551-w. Epub 2023 Apr 12.
a non-negligent opportunistic pathogen of the family enlisted recently in the global priority pathogens by WHO for its swift propensity to acquire drug-resistant genes, engendering enhanced death rates. A combination of diverse antimicrobials could be recycled to overcome the ongoing acquisition of resistance mechanisms by . Herein, we investigated the in vitro synergistic effect of colistin with meropenem, rifampicin, minocycline and linezolid against three intrinsic colistin-resistant strains collected from critical departments of tertiary care hospitals. The strains were identified and tested for antimicrobial susceptibility by VITEK 2 automated system. The 16S rRNA sequencing was used to reconfirm the species identification. Minimum inhibitory concentrations (MICs) of colistin, meropenem, rifampicin, minocycline and linezolid were determined by the broth microdilution method. Synergistic interactions were studied by checkerboard and time-kill assay. The VITEK 2 identification and 16S rRNA sequencing confirmed that the strains were . The automated antimicrobial susceptibility test revealed that all three isolates were multi-drug resistant. The checkerboard analysis demonstrated the synergy of all four combinations with FICI values ranging from 0.06 to 0.31 in all three isolates. These results suggest a potential role of meropenem as an adjuvant for treating infections. The current work presented the first evidence of synergy between colistin and other antibiotics against infection, which needs validation through in vitro and in vivo studies using a larger number of isolates.
The online version contains supplementary material available at 10.1007/s13205-023-03551-w.
这是一种非疏忽性机会致病菌，最近因其迅速获得耐药基因的倾向以及导致死亡率上升，被世界卫生组织列入全球重点病原体名单。多种抗菌药物联合使用可能有助于克服其持续获得耐药机制的问题。在此，我们研究了黏菌素与美罗培南、利福平、米诺环素和利奈唑胺对从三级医院重症科室收集的三株固有耐黏菌素菌株的体外协同作用。通过VITEK 2自动化系统对菌株进行鉴定和药敏试验。采用16S rRNA测序重新确认菌种鉴定。通过肉汤微量稀释法测定黏菌素、美罗培南、利福平、米诺环素和利奈唑胺的最低抑菌浓度（MIC）。通过棋盘法和时间杀菌试验研究协同相互作用。VITEK 2鉴定和16S rRNA测序证实这些菌株为……。自动化药敏试验显示所有三株分离株均对多种药物耐药。棋盘分析表明所有四种组合均具有协同作用，在所有三株分离株中FICI值范围为0.06至0.31。这些结果表明美罗培南作为治疗……感染辅助药物的潜在作用。目前的工作首次证明了黏菌素与其他抗生素联合治疗……感染的协同作用，这需要通过使用大量分离株的体外和体内研究进行验证。
在线版本包含可在10.1007/s13205-023-03551-w获取的补充材料。
